Loading...Loading...The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of maj ...

Agenus (AGEN) shares rallied 6.8% in the last trading session to close at $5.31. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 55.8% loss over the past four weeks.Earlier this month, the company announced updated data from its phase I study evaluating the BOT/BAL combination therapy in patients with metastatic colorectal cancer that is not microsatellite instability-high (MSS) or deficient mismatch repair ( ...

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.The past nine months have been rough ones to be an Agenus (AGEN -0.43%) shareholder. The stock has collapsed by about 75% from the peak it set last June.Investment bank analysts on Wall Street who follow the Massachusetts-headquartered cancer drug developer think it's been underappreciated. For example, B. Riley recently reiterated a buy rating for Agenus with a $5 price target.Agenus shares could deliver an enormo ...

These stocks could rocket higher, but they also present significant risks.Investors looking for stocks that can produce dramatic gains over the next 12 months want to turn their attention to the biotechnology industry. Wall Street analysts tasked with following a synthetic biology company called Ginkgo Bioworks (DNA -6.25%) think it can more than double your money.Investment bankers also have high hopes for Agenus (AGEN -12.85%). The latest price targets on the cancer drug developer suggest it can shoot mor ...

Here’s the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I’m not just talking about the price of the securities themselves. Indeed, these lesser-known enterprises are relatively low priced.No, the cost comes in the fact that extreme speculation such as this involves an inverse relationship. For maximum potential upside, you typically need to absorb the minimal amount of predictability. Let’s consider blue-chip stocks. Generally, you can be profitable with these securit ...

Agenus Inc. (NASDAQ:AGEN) Q4 2023 Results Conference Call March 14, 2024 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and Chief Executive Officer Steven O'Day - Chief Medical Officer Christine Klaskin - VP, Finance and Principal Financial and Accounting Officer Todd Yancy - Chief Strategic Advisor Conference Call Participants Emily Bodnar - H.C. Wainright Mayank Mamtani - B. Riley Securities Colleen Kusy - Baird Matthew Phipps - William Blair Operator Good mo ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. “In 2023, Agenus made significant advances across our BOT/BAL development program. Our first target indication is metastatic, refractory colorectal cancer that is not MSI-H/dMMR, for which we are focused on pursuing accelerated approva ...

Financial Performance - Research and development revenue increased to approximately $38.8 million in 2023 from $17.0 million in 2022, primarily due to a $25.0 million milestone under the BMS License Agreement[410]. - Non-cash royalty revenue related to GSK increased by $69.3 million to approximately $114.6 million in 2023, driven by increased net sales of GSK's vaccines containing the QS-21 STIMULON adjuvant[411]. - The accumulated deficit as of December 31, 2023, reached $1.96 billion, indicating significant losses since inception[408]. - Non-operating income decreased by $12.5 million to $37,000 for the year ended December 31, 2023, compared to $12.6 million in 2022, primarily due to minimal activity in 2023[415]. - Interest expense, net increased to $97.9 million for the year ended December 31, 2023, from $61.9 million in 2022, mainly due to increased non-cash interest related to the Royalty Purchase Agreement[416]. - The accumulated deficit reached $1.96 billion as of December 31, 2023, with expectations of significant losses continuing over the next several years[426]. - Cash, cash equivalents, and short-term investments decreased to $76.1 million as of December 31, 2023, down by $117.2 million from the previous year[431]. - Net cash used in operating activities was $224.2 million for the year ended December 31, 2023, compared to $175.4 million in 2022[437]. Research and Development - The company’s research and development expenses for 2023 were $234.6 million, up from $186.7 million in 2022[408]. - R&D expenses increased by 26% to $234.6 million for the year ended December 31, 2023, up from $186.7 million in 2022, primarily due to a $44.6 million increase in third-party services and other expenses[413]. - Total research and development expenses for 2023 amounted to $234.6 million, with significant costs associated with antibody programs[419]. - The company launched SaponiQx to innovate in adjuvant discovery and vaccine design, focusing on the next-generation QS-21 STIMULON[404]. - Botensilimab, the lead program, received Fast Track designation from the FDA for treating patients with dMMR metastatic colorectal cancer, with plans to submit a BLA by the end of 2024[395]. - The company completed enrollment of approximately 150 patients in a Phase 1 trial and 230 patients in a randomized Phase 2 trial for botensilimab by October 2023[395]. - The company is pursuing a global regulatory strategy for botensilimab, aiming for accelerated approval in the U.S. and Europe[395]. Collaborations and Agreements - The company has established collaborations with several firms, including BMS and Merck, resulting in potential milestone payments exceeding $1.32 billion from BMS alone[403][396]. - The Gilead Collaboration Agreements could yield up to $520.0 million in milestone payments and royalties on future sales[400]. - The company plans to enter into additional agreements with third-party providers, estimating total payments of $645.4 million over the term of related activities[435]. Financial Obligations and Risks - Long-term debt totals $14.384 billion, with less than $1.242 billion due in the next year[439]. - Operating leases amount to $119.297 million, with payments due between 2025 and 2036[439]. - Finance leases total $16.559 million, with $11.669 million due in the next year[439]. - The company is in discussions for potential structured financing and corporate collaborations to extend cash resources[433]. - The company is exposed to fluctuations in interest rates as it seeks debt financing and invests excess cash[448]. - Approximately 1.0% of cash used in operations for 2023 was from foreign subsidiaries, indicating exposure to foreign currency exchange rate fluctuations[447]. - The company does not currently employ hedging strategies to manage foreign currency exchange rate risks[447]. - The investment policy prohibits investing in structured investment vehicles and asset-backed commercial paper, focusing on preserving principal and maximizing yields[449]. - Non-cash interest expense related to the HCR Royalty Purchase Agreement is recorded based on estimated royalty payments from GSK, which could vary significantly[443]. - The company periodically reviews and amends its investment policy as necessary to manage credit risk and maintain liquidity[449].

Agenus Reports Fourth Quarter and Full Year 2023 Results FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1st and 2nd line standard of care treatments Data from Phase 1 of BOT/BAL in refractory CRC showed durable ORR of 24% in patients with non-active liver metastases (NLM); Completed enrollment of randomized Phase 2 trial (n=230) Clinical data sets path for expansion opportunities in pancreas, lung, neoadjuvant CRC, and melanoma LEXING ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade compared to ...